drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
An allogeneic engineered cellular immunotherapy composed of γδ T cells expressing a chimeric antigen receptor targeting B7-H3 (CD276). Administered via local (meningeal/CSF) injection at 3×10^7 cells per dose with optional repeat dosing. CAR engagement enables MHC-independent recognition of B7-H3+ tumor cells, activating T-cell signaling for cytotoxic killing (perforin/granzyme) and cytokine release; γδ T cells contribute innate-like stress-antigen recognition (e.g., via γδ TCR/NKG2D) with lower alloreactivity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intrathecal
drug_mechanism_of_action
Allogeneic γδ T cells engineered with a chimeric antigen receptor targeting B7‑H3 (CD276) recognize tumor cells independently of MHC and, upon CAR engagement, activate T‑cell signaling to mediate cytotoxic killing via perforin/granzyme and cytokine release; the γδ T-cell phenotype adds innate-like stress‑antigen recognition (e.g., via γδ TCR/NKG2D) with lower alloreactivity.
drug_name
QH104 (B7-H3–targeted CAR-γδ T cells)
nct_id_drug_ref
NCT06592092